Business
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients
About this update from Mineralys Therapeutics, Inc.
[{"type":"text","content":"– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension – –Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm – – Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype for enhanced response to lorundrostat treatment – RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2–5. In this new analysis, investigators identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure (BP) of 32 millimeters of mercury (mmHg). The enhanced response was proportional to the elevation in body mass index (BMI) and may indicate an obesity-related, aldosterone-dependent hypertensive endotype. “We were able to show in this post-hoc analysis additional evidence corroborating the association between BMI and blood pressure reduction with lorundrostat. Individuals trying to manage obesity and hypertension in tandem are at an increased risk for poor outcomes, and a treatment that can provide an enhanced response to this population holds great promise,” stated David Rodman, M.D., Chief Medical Officer for Mineralys. “We continue to believe that we’re entering a precision-medicine era when it comes to hypertension treatments – an era in which physicians can identify and confidently prescribe an anti-hypertensive treatment for each patient according to their underlying biological factors, such as obese individuals with aldosterone-dependent hypertension.” Consistent wi...